PMID- 17724013
OWN - NLM
STAT- MEDLINE
DCOM- 20071018
LR  - 20181201
IS  - 1945-1997 (Electronic)
IS  - 0098-6151 (Linking)
VI  - 107 Suppl
DP  - 2007 May
TI  - Application of incretin mimetics and dipeptidyl peptidase IV inhibitors in 
      managing type 2 diabetes mellitus.
PG  - S10-6
AB  - Approximately two thirds of patients with type 2 diabetes mellitus (T2DM) are 
      unable to reach the hemoglobin A(1c) target set by the American Diabetes 
      Association (HbA(1c) <7.0%). Therefore, T2DM continues to be a major public 
      health concern. Incretin mimetics and dipeptidyl peptidase IV inhibitors are 
      medications that have the potential to improve patients' glycemic control, as 
      well as to result in beneficial socioeconomic effects. Research suggests that 
      significant benefits are to be gained from incretin mimetics and dipeptidyl 
      peptidase IV inhibitors, either one used as monotherapy or used together as 
      combination therapy. However, the benefits and risks of these agents need to be 
      evaluated more thoroughly, with emphasis on such adverse effects as edema, 
      hypoglycemia, and weight gain.
FAU - Boyle, Patrick J
AU  - Boyle PJ
AD  - University of New Mexico, Albuquerque, NM 87131-0001, USA. pboyle@salud.unm.edu
FAU - Freeman, Jeffrey S
AU  - Freeman JS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - J Am Osteopath Assoc
JT  - The Journal of the American Osteopathic Association
JID - 7503065
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Peptides)
RN  - 0 (Venoms)
RN  - 59392-49-3 (Gastric Inhibitory Polypeptide)
RN  - 839I73S42A (Liraglutide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 9P1872D4OL (Exenatide)
RN  - EC 3.4.14.5 (Dipeptidyl Peptidase 4)
SB  - IM
MH  - Diabetes Mellitus, Type 2/*drug therapy/physiopathology
MH  - Dipeptidyl Peptidase 4/therapeutic use
MH  - *Dipeptidyl-Peptidase IV Inhibitors
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Exenatide
MH  - Female
MH  - Gastric Inhibitory Polypeptide/therapeutic use
MH  - Glucagon-Like Peptide 1/*analogs & derivatives/therapeutic use
MH  - Humans
MH  - Hyperglycemia/drug therapy
MH  - Hypoglycemic Agents/therapeutic use
MH  - Liraglutide
MH  - Male
MH  - Peptides/*therapeutic use
MH  - Probability
MH  - Prognosis
MH  - Treatment Outcome
MH  - Venoms/*therapeutic use
RF  - 31
EDAT- 2007/09/19 09:00
MHDA- 2007/10/19 09:00
CRDT- 2007/09/19 09:00
PHST- 2007/09/19 09:00 [pubmed]
PHST- 2007/10/19 09:00 [medline]
PHST- 2007/09/19 09:00 [entrez]
AID - 107/suppl_3/S10 [pii]
PST - ppublish
SO  - J Am Osteopath Assoc. 2007 May;107 Suppl:S10-6.